Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Candesartan.

Christoph H Gleiter1, Chrstine Jägle, Ursula Gresser

  • 1Universitätsklinikum Tübingen, Institut für Pharmakologie und Toxikologie, Abteilung Klinische Pharmakologie, Otfried-Müller-Strasse 45, D-72076 Tübingen, Germany. christoph.gleiter@med.uni-tuebingen.de

Cardiovascular Drug Reviews
|December 14, 2004
PubMed
Summary

Candesartan cilexetil effectively treats hypertension and heart failure by blocking angiotensin II. This drug is well-tolerated across various patient groups, showing similar efficacy and safety to placebo.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Losartan Improves Memory, Neurogenesis and Cell Motility in Transgenic Alzheimer's Mice.

Pharmaceuticals (Basel, Switzerland)·2021
Same author

Cell motility and migration as determinants of stem cell efficacy.

EBioMedicine·2020
Same author

Antifibrotic Effects of Amyloid-Beta and Its Loss in Cirrhotic Liver.

Cells·2020
Same author

Intranasal Losartan Decreases Perivascular Beta Amyloid, Inflammation, and the Decline of Neurogenesis in Hypertensive Rats.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2019
Same author

Side Effects and Interactions of the Xanthine Oxidase Inhibitor Febuxostat.

Pharmaceuticals (Basel, Switzerland)·2018
Same author

Chronic Heart Failure.

Deutsches Arzteblatt international·2018

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Candesartan cilexetil is a prodrug for candesartan, an angiotensin II receptor antagonist.
  • It selectively blocks angiotensin II type 1 receptors, inhibiting angiotensin II's effects.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of candesartan cilexetil.
  • To assess its use in hypertension, heart failure, and diabetic nephropathy.

Main Methods:

  • Clinical trials were conducted across various patient populations.
  • Efficacy was assessed at doses ranging from 2 to 32 mg daily.
  • Pharmacokinetics and tolerability were evaluated in specific subgroups.

Main Results:

  • Demonstrated efficacy in all grades of hypertension, heart failure, and reducing urinary albumin excretion in diabetics.

Related Experiment Videos

  • Pharmacokinetics are similar in elderly patients and unaffected by hepatic impairment (up to 12 mg/day).
  • No dose adjustment needed for mild to moderate renal impairment; tolerability is comparable to placebo.

    • Conclusions:

    • Candesartan cilexetil is effective for hypertension, heart failure, and diabetic nephropathy.
    • It exhibits favorable pharmacokinetics and tolerability across diverse patient demographics.
    • Adverse events are generally mild, infrequent, and similar to placebo.